alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
§ 133.138 Edam cheese. ( a ) *Description.* ( 1 ) Edam cheese is the food prepared by the procedure set forth in paragraph (a)(3) of this section or by any other procedure which produces a finished cheese having the same physical and chemical properties. The minimum milkfat content is 40 percent by weight of the solids and the maximum moisture content is 45 percent by weight, as determined by the methods described in § 133.5. If the dairy ingredients used are not pasteurized, the cheese is cured at a temperature of not less than 35 °F for at least 60 days.
( 2 ) If pasteurized dairy ingredients are used, the phenol equivalent value of 0.25 gram of edam cheese is not more than 3 micrograms, as determined by the method described in § 133.5.
( 3 ) One or more of the dairy ingredients specified in paragraph (b)(1) of this section may be warmed and is subjected to the action of a lactic acid-producing bacterial culture. One or more of the clotting enzymes specified in paragraph (b)(2) of this section is added to set the dairy ingredients to a semisolid mass. After coagulation the mass is cut into small cube-shaped pieces with sides approximately three-eighths-inch long. The mass is stirred and heated to about 90 °F. and so handled by further stirring, heating, dilution with water or salt brine, and salting as to promote and regulate the separation of curd and whey. When the desired curd is obtained, it is transferred to forms permitting drainage of whey. During drainage the curd is pressed and turned. After drainage the curd is removed from the forms and is salted and cured. One or more of the other optional ingredients specified in paragraph (b)(3) of this section may be added during the procedures.
( b ) *Optional ingredients.* The following safe and suitable ingredients may be used: ( 1 ) *Dairy ingredients.* Milk, nonfat milk, or cream, as defined in § 133.3, used alone or in combination.
( 2 ) *Clotting enzymes.* Rennet and/or other clotting enzymes of animal, plant, or microbial origin.
( 3 ) *Other optional ingredients.* ( i ) Coloring.
( ii ) Calcium chloride in an amount not more than 0.02 percent (calculated as anhydrous calcium chloride) of the weight of the dairy ingredients, used as a coagulation aid.
( iii ) Enzymes of animal, plant, or microbial origin, used in curing or flavor development.
( iv ) Antimycotic agents, the cumulative levels of which shall not exceed current good manufacturing practice, may be added to the surface of the cheese.
( c ) *Nomenclature.* The name of the food is “edam cheese.”
( d ) *Label declaration.* Each of the ingredients used in the food shall be declared on the label as required by the applicable sections of parts 101 and 130 of this chapter, except that: ( 1 ) Enzymes of animal, plant, or microbial origin may be declared as “enzymes”; and
( 2 ) The dairy ingredients may be declared, in descending order of predominance, by the use of the terms “milkfat and nonfat milk” or “nonfat milk and milkfat,” as appropriate.
[48 FR 2743, Jan. 21, 1983; 48 FR 11426, Mar. 18, 1983, as amended at 55 FR 6795, Feb. 27, 1990; 58 FR 2893, Jan. 6, 1993]
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7276 Introduced in House (IH)]

<DOC>

118th CONGRESS
  2d Session
                                H. R. 7276

To amend the Internal Revenue Code of 1986 to repeal the excise tax on 
              telephone and other communications services.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                            February 7, 2024

Mr. Connolly (for himself and Mr. Thompson of Pennsylvania) introduced 
  the following bill; which was referred to the Committee on Ways and 
                                 Means

_______________________________________________________________________

                                 A BILL

 
To amend the Internal Revenue Code of 1986 to repeal the excise tax on 
              telephone and other communications services.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Telephone Excise Tax Repeal Act of 
2024''.

SEC. 2. REPEAL OF EXCISE TAX ON TELEPHONE AND OTHER COMMUNICATIONS 
              SERVICES.

    (a) In General.--Chapter 33 of the Internal Revenue Code of 1986 
(relating to facilities and services) is amended by striking subchapter 
B.
    (b) Conforming Amendments.--
            (1) Section 4293 of the Internal Revenue Code of 1986 is 
        amended by striking ``chapter 32 (other than the taxes imposed 
        by sections 4064 and 4121) and subchapter B of chapter 33,'' 
        and inserting ``and chapter 32 (other than the taxes imposed by 
        sections 4064 and 4121),''.
            (2) Paragraph (1) of section 6302(e) of such Code is 
        amended by striking ``section 4251 or''.
            (3) Paragraph (2) of section 6302(e) of such Code is 
        amended--
                    (A) by striking ``imposed by section 4251, 4261, or 
                4271 with respect to'' and inserting ``imposed by 
                section 4261 or 4271 with respect to'', and
                    (B) by striking ``bills rendered or''.
            (4) The subsection heading for section 6302(e) of such Code 
        is amended by striking ``Communications Services and''.
            (5) Section 6415 of such Code is amended by striking 
        ``4251, 4261, or 4271'' each place it appears and inserting 
        ``4261 or 4271''.
            (6) Paragraph (2) of section 7871(a) of such Code is 
        amended by inserting ``or'' at the end of subparagraph (B), by 
        striking subparagraph (C), and by redesignating subparagraph 
        (D) as subparagraph (C).
            (7) The table of subchapters for chapter 33 of such Code is 
        amended by striking the item relating to subchapter B.
    (c) Effective Date.--The amendments made by this section shall 
apply to amounts paid pursuant to bills first rendered more than 90 
days after the date of the enactment of this Act.
                                 <all>
```
### IN THE SUPREME COURT OF THE STATE OF MONTANA DA 22

-0235

_________________ N.B., K.M.B., K.R.B., and K.R.B.,

Plaintiffs and Appellants,

v. MONTANA DEPARTMENT OF PUBLIC HEALTH AND HUMAN SERVICES, a Montana State Agency, VALLEY COUNTY, a Montana county, CYNDI BAILLARGEON, individually and as a DPHHS employee, and DOES 1

-X,

Defendants and Appellees. O R D E R

_________________ Plaintiffs and Appellants have moved to dismiss this appeal on the grounds that the order they sought to appeal is not a final judgment for purposes of appeal pursuant to M. R. App. P. 4(1)(a). Defendants and Appellees do not object to Appellants’ motion. IT IS THEREFORE ORDERED that this appeal is DISMISSED WITHOUT PREJUDICE.

Electronically signed by: Mike McGrath Chief Justice, Montana Supreme Court

June 16 2022

06/16/2022

Case Number: DA 22-0235
<PAGE>   1
                                                                     EXHIBIT 5.1

                    [Letterhead of Preston Gates & Ellis LLP]

                                 April 21, 1998



SeaMED Corporation
14500 Northeast 87th Street
Redmond, Washington 98052-3431

      Re:   Registration Statement on Form S-8 of SeaMED Corporation;
            1995 SeaMED Corporation Stock Option and Incentive Plan

Ladies and Gentlemen:

      We have acted as counsel to SeaMED Corporation (the "Company") in
connection with the filing of the above-referenced Registration Statement (the
"Registration Statement") relating to the registration of 300,000 additional
shares (the "Shares") of Common Stock, no par value per share, of the Company
issuable under the Company's 1995 Stock Option Plan. In connection therewith, we
have reviewed the Company's Articles of Incorporation, Bylaws, minutes of
appropriate meetings, a copy of the Plan and such other matters we deemed
appropriate.

      Based on that review, it is our opinion that the Shares will be, when sold
pursuant to the terms contemplated by the Registration Statement, validly
issued, fully paid and non-assessable under the Washington Business Corporation
Act.

      We hereby consent to the filing of this opinion as an exhibit to the
Registration Statement and to all references to our firm included in or made a
part of the Registration Statement.


                                    Very truly yours,

                                    PRESTON GATES & ELLIS LLP

                                    /s/ Mark R. Beatty

                                    By
                                        Mark R. Beatty
###### Editorial Note on Part 312

#### Editorial Note:

Nomenclature changes to part 312 appear at 69 FR 13717, Mar. 24, 2004.

#### § 312.87 Active monitoring of conduct and evaluation of clinical trials.

For drugs covered under this section, the Commissioner and other agency officials will monitor the progress of the conduct and evaluation of clinical trials and be involved in facilitating their appropriate progress.
Exhibit








Exhibit 10.2


Amendment No. 4
to the Edwards Lifesciences Corporation 401(k)
Savings and Investment Plan
(Effective January 1, 2016)






The Edwards Lifesciences Corporation 401(k) Savings and Investment Plan ("Plan") as amended and restated as of January 1, 2016 is amended effective April 1, 2017, unless specified otherwise:


1. The first paragraph of Section 5.1 is amended to read as follows:


5.1  Pay Deferral Contributions. An Eligible Employee may elect in the manner described below to have his Employer reduce his Compensation via payroll deduction in an amount not less than 1% nor more than 25% (prior to January 1,  2003, the maximum percentage was 15%) of his Compensation, in whole multiples of 1%.  Such salary reductions shall constitute Pay Deferral Contributions and shall be contributed to the Trust by the Employer in accordance with Section 4.1.  An initial election shall be made under this Section 5.1 with respect to any Participant hired on or after January 1, 2017, in the form of an automatic 3% before-tax Pay Deferral Contribution unless the Participant elects a different rate or no deferral.  Effective April 1, 2017, if a Participant has elected a salary deferral percentage of less than 5%, such Participant’s salary deferral percentage shall automatically be increased 1% each Plan Year (not to exceed 5%) unless such Participant has affirmatively elected otherwise.  The 1% automatic escalator shall be effective May of each Plan Year.  The automatic escalator shall be in the form of a before-tax Pay Deferral Contribution unless the participant has elected 100% of Deferral Contributions to be in the form of a Roth Contribution.
IN WITNESS WHEREOF, a duly authorized officer of the Company and a member of the Administrative and Investment Committee has caused this Plan to be executed on the 24th day of February, 2017.


EDWARDS LIFESCIENCES
CORPORATION ADMINISTRATIVE
AND INVESTMENT COMMITTEE






By:  /s/ Christine Z. McCauley
Christine Z. McCauley
Chairperson, Administrative and Investment Committee
```

[Congressional Bills 109th Congress]
[From the U.S. Government Publishing Office]
[H. Res. 981 Engrossed in House (EH)]

H. Res. 981

                In the House of Representatives, U. S.,

                                                     September 7, 2006.
    Resolved, That at any time after the adoption of this resolution the Speaker 
may, pursuant to clause 2(b) of rule XVIII, declare the House resolved into the 
Committee of the Whole House on the state of the Union for consideration of the 
bill (H.R. 503) to amend the Horse Protection Act to prohibit the shipping, 
transporting, moving, delivering, receiving, possessing, purchasing, selling, or 
donation of horses and other equines to be slaughtered for human consumption, 
and for other purposes. The first reading of the bill shall be dispensed with. 
All points of order against consideration of the bill are waived. General debate 
shall be confined to the bill and shall not exceed one hour and twenty minutes 
equally divided and controlled by the Majority Leader and the Minority Leader or 
their designees. After general debate the bill shall be considered for amendment 
under the five-minute rule. The bill shall be considered as read. 
Notwithstanding clause 11 of rule XVIII, no amendment shall be in order except 
those printed in the report of the Committee on Rules accompanying this 
resolution. Each such amendment may be offered only in the order printed in the 
report, may be offered only by a Member designated in the report, shall be 
considered as read, shall be debatable for the time specified in the report 
equally divided and controlled by the proponent and an opponent, shall not be 
subject to amendment, and shall not be subject to a demand for division of the 
question in the House or in the Committee of the Whole. All points of order 
against such amendments are waived. At the conclusion of consideration of the 
bill for amendment the Committee shall rise and report the bill to the House 
with such amendments as may have been adopted. The previous question shall be 
considered as ordered on the bill and amendments thereto to final passage 
without intervening motion except one motion to recommit with or without 
instructions.
            Attest:

                                                                          Clerk.
```
================================================================================

EXHIBIT 32.1

                CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



In connection  with the Quarterly  Report of CirTran  Corporation on Form 10-QSB
for the period  ending  September  30, 2006,  as filed with the  Securities  and
Exchange Commission on the date hereof (the "Report"), Iehab Hawatmeh, President
of the  Company,  certifies,  pursuant  to 18 U.S.C.  Section  1350,  as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of
the Securities Exchange Act of 1934; and

(2) The  information  contained in the Report fairly  presents,  in all material
respects, the financial condition and result of operations of the Company.

May 21, 2007

                                            /s/ Iehab J. Hawatmeh
                                            ----------------------
                                            Iehab J. Hawatmeh
                                            President















--------------------------------------------------------------------------------
###### Editorial Note on Part 184

#### Editorial Note:

Nomenclature changes to part 184 appear at 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 69 FR 13717, Mar. 24, 2004; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; and 81 FR 49897, July 29, 2016.

#### § 184.1187 Calcium alginate.

(a) Calcium alginate (CAS Reg. No. 9005-35-0) is the calcium salt of alginic acid, a natural polyuronide constituent of certain brown algae. Calcium alginate is prepared by the neutralization of purified alginic acid with appropriate pH control agents, or from sodium alginate by metathesis with appropriate calcium salts.

(b) The ingredient meets the specifications of the Food Chemicals Codex, 3d Ed. (1981), p. 45, which is incorporated by reference. Copies are available from the National Academy Press, 2101 Constitution Ave. NW., Washington, DC 20418, or available for inspection at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: *http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html.*

(c) In accordance with § 184.1(b)(2), the ingredient is used in food only within the following specific limitations:

| Category of food | Maximum level of use in food (as served) (percent) | Functional use |
| --- | --- | --- |
| Baked goods, § 170.3(n)(1) of this chapter | 0.002 | Stabilizer, thickener, § 170.3(o)(28) of this chapter. |
| Alcoholic beverages, § 170.3(n)(2) of this chapter | 0.4 | Do. |
| Confections and frostings, § 170.3(n)(9) of this chapter | 0.4 | Do. |
| Egg products, § 170.3(n)(11) of this chapter | 0.6 | Do. |
| Fats and oils, § 170.3(n)(12) of this chapter | 0.5 | Do. |
| Gelatins, puddings, § 170.3(n)(22) of this chapter | 0.25 | Do. |
| Gravies and sauces, § 170.3(n)(24) of this chapter | 0.4 | Do. |
| Jams and jellies, § 170.3(n)(28) of this chapter | 0.5 | Do. |
| Sweet sauces, § 170.3(n)(43) of this chapter | 0.5 | Do. |
| All other food categories | 0.3 | Do. |

(d) Prior sanctions for calcium alginate different from the uses established in this section do not exist or have been waived.

[47 FR 29951, July 9, 1982]
Fourth Court of Appeals

San Antonio, Texas

October 28, 2020

No. 04-20-00296-CR

Neil Howard MCGINNIS,

Appellant

v.

The STATE of Texas,

Appellee

From the 451st Judicial District Court, Kendall County, Texas

Trial Court No. 6781

Honorable Kirsten Cohoon, Judge Presiding

O R D E R

On August 26, 2020, we abated this appeal and remanded the cause to the trial court to 

determine, inter alia, whether Appellant wanted court-appointed counsel. As ordered, the trial 

court held a hearing, made findings of fact and conclusions of law, and appointed counsel to 

represent Appellant in this appeal. The trial court clerk and reporter each filed supplemental 

records.

We REINSTATE this appeal on this court’s docket. Appellant’s brief is due November 

23, 2020. See TEX. R. APP. P. 38.6(a). 

_________________________________

Patricia O. Alvarez, Justice

IN WITNESS WHEREOF, I have hereunto set my hand and affixed the seal of the said 

court on this 28th day of October, 2020.

___________________________________

MICHAEL A. CRUZ, 

Clerk of Court
<PAGE>


                                                                    Exhibit 21


                         SUBSIDIARIES OF THE REGISTRANT

                                                              Jurisdiction
                  Subsidiaries (a)                          of Incorporation
                 -------------------                      --------------------

Victoria's Secret Stores, Inc. (b)                               Delaware
Victoria's Secret Catalogue, LLC (c)                             Delaware
Bath & Body Works, Inc. (d)                                      Delaware
Gryphon Development, Inc. (e)                                    Delaware
Intimate Brands Service Corporation (f)                          Delaware

(a)      The names of certain subsidiaries are omitted since such unnamed
         subsidiaries, considered in the aggregate as a single subsidiary, would
         not constitute a significant subsidiary as of January 29, 2000.

(b)      Victoria's Secret Stores, Inc. is a wholly-owned subsidiary of the
         registrant.

(c)      Victoria's Secret Catalogue, LLC is a wholly-owned subsidiary of
         Victoria's Secret Catalogue Holding LLC, a Delaware limited liability
         corporation and a wholly-owned subsidiary of the registrant.

(d)      Bath & Body Works, Inc. is a wholly-owned subsidiary of the registrant.

(e)      Gryphon Development, Inc. is a wholly-owned subsidiary of the Gryphon
         Holding Corporation, a Delaware corporation and a wholly-owned
         subsidiary of the registrant.

(f)      Intimate Brands Service Corporation is a wholly-owned subsidiary of the
         registrant.
§ 1141.12 Misbranding of cigarettes. ( a ) A cigarette will be deemed to be misbranded under section 903(a)(1) of the Federal Food, Drug, and Cosmetic Act if its package does not bear one of the required warnings in accordance with section 4 of the Federal Cigarette Labeling and Advertising Act and this part. A cigarette will be deemed to be misbranded under section 903(a)(7)(A) of the Federal Food, Drug, and Cosmetic Act if its advertising does not bear one of the required warnings in accordance with section 4 of the Federal Cigarette Labeling and Advertising Act and this part.
( b ) A cigarette advertisement and other descriptive printed matter issued or caused to be issued by the manufacturer, packer, or distributor will be deemed to include a brief statement of relevant warnings for the purposes of section 903(a)(8) of the Federal Food, Drug, and Cosmetic Act if it bears one of the required warnings in accordance with section 4 of the Federal Cigarette Labeling and Advertising Act and this part. A cigarette distributed or offered for sale in any State shall be deemed to be misbranded under section 903(a)(8) of the Federal Food, Drug, and Cosmetic Act unless the manufacturer, packer, or distributor includes in all advertisements and other descriptive printed matter issued or caused to be issued by the manufacturer, packer, or distributor with respect to the cigarette one of the required warnings in accordance with section 4 of the Federal Cigarette Labeling and Advertising Act and this part.
**Exhibit 32.2**

 

CERTIFICATIONPURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTEDPURSUANT TO

SECTION 906OF THE SARBANES-OXLEY ACT OF 2002

 

In connectionwith the accompanying annual report of American Cannabis Company, Inc. (the "Company") on Form 10-K for the year endedDecember 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), Michael Schwanbeck,Chief Financial Officer of the Company, certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of theSarbanes-Oxley Act of 2002, that to my knowledge:

 

(1) The Reportfully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) The informationcontained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

/s/ Michael Schwanbeck

 

Michael Schwanbeck

Chief Financial Officer

(Principal Financial Officer)

 

Date: December 26, 2018